Saltar al contenido
Merck

N129

Sigma-Aldrich

Naloxone methiodide

≥98% (HPLC), solid

Sinónimos:

(5α,17R)-4,5-Epoxy-3,14-dihydroxy-17-methyl-6-oxo-17-(2-propenyl)-morphinanium iodide, N-Methylnaloxonium iodide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C20H24INO4
Número de CAS:
Peso molecular:
469.31
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (HPLC)

form

solid

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

color

white to tan

solubility

H2O: >10 mg/mL

storage temp.

2-8°C

SMILES string

[I-].[H][C@]12Oc3c(O)ccc4C[C@@H]5[C@](O)(CCC1=O)[C@@]2(CC[N@+]5(C)CC=C)c34

InChI

1S/C20H23NO4.HI/c1-3-9-21(2)10-8-19-16-12-4-5-13(22)17(16)25-18(19)14(23)6-7-20(19,24)15(21)11-12;/h3-5,15,18,24H,1,6-11H2,2H3;1H/t15-,18+,19+,20-,21?;/m1./s1

InChI key

ICONPJDAXITIPI-UXYWFNEESA-N

Application

Naloxone methiodide has been used as inhibitor of opioid receptor in fish and mice. Naloxone methiodide has been used to block opioid neurotransmission.

Biochem/physiol Actions

Naloxone methiodide has low affinity for opioid receptors than naloxone. Administration of naloxone inhibits opioid receptor and opioid-induced respiratory depression.
Quaternary salt of naloxone that, like the parent compound, is a nonselective antagonist at opioid receptors. It does not cross the blood-brain barrier.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Po-Kuan Chao et al.
PloS one, 7(8), e43680-e43680 (2012-09-01)
Recent studies have shown that opioid treatment can reduce pro-inflammatory cytokine production and counteract various neuropathic pain syndromes. Granulocyte colony-stimulating factor (G-CSF) can promote immune cell differentiation by increasing leukocytes (mainly opioid-containing polymorphonuclear (PMN) cells), suggesting a potential beneficial role
M Makino et al.
British journal of pharmacology, 130(6), 1269-1274 (2000-07-25)
1. We investigated the mechanism by which human interferon-alpha (IFN-alpha) increases the immobility time in a forced swimming test, an animal model of depression. 2. Central administration of IFN-alpha (0.05 - 50 IU per mouse, i.cist.) increased the immobility time
G L Chien et al.
Basic research in cardiology, 94(2), 136-143 (1999-05-18)
The hypothesis that naloxone blockade of ischemic preconditioning (IP)-induced infarct limitation does not require central nervous system participation was evaluated using quaternary naloxone in anesthetized rabbits (Study I) and naloxone hydrochloride in isolated rabbit hearts (Study II). In Study I
Jamie L Laprairie et al.
Frontiers in behavioral neuroscience, 3, 31-31 (2009-10-29)
Studies in both rodents and humans have shown that acute inflammatory pain experienced during the perinatal period produces long-term decreases in pain sensitivity (hypoalgesia) (Grunau et al., 1994a, 2001; Ren et al., 2004; LaPrairie and Murphy, 2007). To date, the
The effect of the mu-opioid receptor antagonist naloxone on extinction of conditioned fear in the developing rat
Kim JH and Richardson R
Learning & Memory, 16(3), 161-1166 (2009)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico